COVID-19’s Damage To Gene Therapy Development May Last Years
US FDA's Peter Marks says the field is robust, but hedges on approval predictions for the coming years because of pandemic’s effect.
US FDA's Peter Marks says the field is robust, but hedges on approval predictions for the coming years because of pandemic’s effect.